Graf Acquisition Corp. IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in The Woodlands, Texas.
IPO Year: 2021
Exchange: NYSE
Website: grafacq.com
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
S-1/A - NKGen Biotech, Inc. (0001845459) (Filer)
S-1/A - NKGen Biotech, Inc. (0001845459) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
Fastest customizable press release news feed in the world
THE WOODLANDS, Texas, Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 4:00 p.m., Eastern time, on September 25, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. The Company has decided to adjourn the Special M
THE WOODLANDS, Texas, Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 10:00 a.m., Eastern time, on September 20, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. As previously announced, the Company has recei
THE WOODLANDS, Texas, Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 4:00 p.m., Eastern time, on September 13, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. As previously announced, the Company has receive
THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR-UN, GFOR-WT))) (the "Company" or "Graf"), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer ("NK") cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy ("SNK02"). In October 2022, the Food and Drug Administration allowed NKGen's Phase I SNK02 clinical trial to proceed per its Investigational New Drug application. NKGen previously announced a proposed business combination wit
Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company's Securities to be Listed on Nasdaq Under Ticker Symbols "NKGN" and "NKGNW" THE WOODLANDS, Texas and SANTA ANA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) ("Graf") and NKGen Biotech, Inc. ("NKGen") on August 14, 2023 announced that Graf's registration statement on Form S-4 (File No. 333-271929) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with NKGen, has been declared effective by the U.S. Securities and Exchange Comm
SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapies, and Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) ("Graf") today announced that Michael Klowden and Kathleen Scott have been nominated to serve as independent members of the Board of Directors (the "Board") of the post-business combination company ("New NKGen"). Assuming the director nominees are elected by the stockholders of Graf at the special meeting of its stockholders to be held
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. ("NKGen"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapies, and Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) ("Graf") will co-host an investor event at the Lotte New York Palace Hotel on July 20, 2023 at 10:00 AM ET. Presentation topics include NKGen's differentiated intellectual property and approach to NK cell therapy for Alzheimer's and Parkinson's diseases, NKGen's Phase 1 clinical trial data of SNK01 to treat patients with Alzheimer's disease, preclini
Graf currently has proxies from more than 65% of its stockholders to approve an extension of the time it has to close the business combination with NKGen to September 29, 2023 (the "Extension"). Votes to approve the Extension will be cast at a special meeting of Graf stockholders to be held on May 22, 2023. If the Extension is approved, Graf's sponsor to deposit additional $0.03 per non-redeeming share, per month (up to $165,000 per month in the aggregate) into Trust Account. Graf Trust Account cash to be moved to an interest-bearing account at Citibank, N.A., with initial annualized yield expected to be approximately 4.75%. No Trust Account cash or interest will be used to pay
NKGen Biotech, Inc. ("NKGen"), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.'s non-genetically modified, enhanced and expanded NK cells have the potential to be a possible treatment for Alzheimer's and Parkinson's diseases and other neurodegenerative and oncological diseasesNKGen is expected to have a pro forma enterprise value of at least $160 million, based on $145 million in pre-money equity value plus conversion to equity at closing of at least $15 million of outstanding private convertible securities and accrued interestInitial Phase I trial data expected to be presented at the American S
This live feed shows all institutional transactions in real time.
SC 13G - NKGen Biotech, Inc. (0001845459) (Subject)
SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)
SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)
SC 13D/A - NKGen Biotech, Inc. (0001845459) (Subject)
SC 13D - NKGen Biotech, Inc. (0001845459) (Subject)
SC 13G - Graf Acquisition Corp. IV (0001845459) (Subject)
SC 13G/A - Graf Acquisition Corp. IV (0001845459) (Subject)
SC 13G - Graf Acquisition Corp. IV (0001845459) (Subject)
SC 13G/A - Graf Acquisition Corp. IV (0001845459) (Subject)